Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Influenza Vaccines in Maintenance Hemodialysis Patients: Does Seroresponse Vary With Different Vaccine Formulations?

Tarek Barbar, Sri Lekha Tummalapalli, and Jeffrey Silberzweig

The COVID-19 pandemic has further highlighted the major role of respiratory illnesses as vaccine-preventable sources of morbidity and mortality for patients on dialysis. Influenza-like illnesses contribute to more than 1,000 excess deaths per year among patients with kidney failure, resulting in a seasonal pattern of mortality. Influenza can cause viral pneumonia, secondary bacterial pneumonias, and multisystem extrapulmonary complications, including heart failure exacerbation. Optimal formulation and timing of influenza vaccinations could decrease the burden of influenza-associated illnesses. Among older adults (>65 years) in the general population, randomized trials have compared a high-dose, trivalent, inactivated influenza vaccine (HD-IIV3; 60 μg of hemagglutinin per strain) to a standard-dose, trivalent, inactivated influenza vaccine (SD-IIV3; 15 μg of hemagglutinin per strain). In a 2014 trial, HD-IIV3 elicited a stronger seroresponse than SD-IIV3, as measured by hemagglutination inhibition (HI) titers, and prevented approximately 1 in 4 influenza illnesses. Serious adverse events were fewer in the HD-IIV3 recipients compared with the SD-IIV3 recipients. This evidence has been extrapolated to the dialysis population. The Advisory Committee on Immunization Practices (ACIP) recommends yearly inactivated or recombinant quadrivalent influenza vaccine (RIV4) for individuals receiving maintenance dialysis. High-dose vaccines are recommended for those receiving maintenance dialysis who are 65 years of age or older. Medicare costs range from $20 for standard-dose influenza vaccines to ~$65 for high-dose and recombinant vaccines.

Although randomized clinical trial evidence comparing influenza vaccine formulations is lacking in the maintenance hemodialysis population, numerous observational studies have sought to address this question. Miskulin et al compared hospitalization and mortality among greater than 9,000 patients at 230 Dialysis Clinic, Inc (DCI) clinics who received different influenza vaccine formulations. During the 2015-2016 season, there were no significant differences in adjusted rates of hospitalizations and mortality in patients receiving HD-IIV3, SD-IIV3, or standard-dose quadrivalent influenza vaccine (SD-IIV4). During the 2016-2017 season, HD-IIV3 was associated with a significant reduction in hospitalization compared with SD-IIV4 (adjusted hazard ratio, 0.93 [95% CI, 0.86-1.00]; P = 0.04) but no significant difference in death. Another study, by Butler et al, compared influenza-like illnesses, hospitalizations, and mortality in 2010-2015 US Renal Data System data among patients who received HD-IIV3 versus SD-IIV3 or SD-IIV4. In addition to adjusting for demographics and comorbidities, the authors accounted for frailty and the receipt of other preventive health services as potential confounders. In contrast to the findings of Miskulin et al, no significant differences in illnesses, hospitalizations, and mortality were observed in the high-dose versus standard-dose groups. Only 2.6% of the study population received HD-IIV3, and it is unknown whether patients deemed at higher risk of adverse influenza-associated outcomes in unobserved ways were more likely to receive it, thereby potentially underestimating its benefits. Research studying the seroresponse to different influenza vaccine formulations in maintenance hemodialysis patients could provide biological plausibility for future studies examining clinical outcomes.

In this issue of *AJKD*, Manley et al study the seroresponse to HD-IIV3, SD-IIV4, or RIV4 in patients receiving maintenance hemodialysis. The authors present a prospective, observational study of 254 patients receiving maintenance hemodialysis during the 2017-2018 influenza season. The study leveraged a natural experiment where different vaccines were used in 4 DCI clinics. Vaccine acceptance was high (98%). One clinic administered HD-IIV3 to all patients, another clinic provided SD-IIV4 to all patients, a third clinic provided RIV4 to all patients, and the fourth clinic provided SD-IIV4 to patients under age 65 and HD-IIV3 to patients age 65 and older.

Seroresponse was examined across 2 dimensions: strength and durability. HI titers were measured from sera collected at 5 different time points: 1 prevaccination (baseline) and 4 postvaccination (months 1, 2, 3, and 4). As the primary outcome, a HI titer of 1:40 or greater was used as a measure of protective seroresponse. A higher threshold of seroprotection, a titer of 1:160 or greater, was assessed as a secondary outcome. Generalized linear models accounted for within-participant correlation and potential confounders including demographics, prior influenza vaccinations, and other measures of dialysis quality.

The results from Manley et al indicate that durability may be the greatest benefit of HD-IIV3. At month 1, patients receiving HD-IIV3 and RIV4 developed robust HI...
titers against influenza A strains (H1N1 and H3N2), which were higher than SD-IIV4 HI titers (illustrated in Figures 1-2 of Manley et al). HD-IIV3–induced titers had longer durability and were higher than those elicited by SD-IIV4 and RIV4 at months 3 and 4. Patients receiving HD-IIV3 were more likely to have seroprotection at an HI titer threshold of ≥1:160 at months 3 and 4, compared with those receiving SD-IIV4 and RIV4 (depicted in Figures 3-4 of Manley et al). There was no significant difference in likelihood of HI titers ≥1:40 between the vaccine types. Seroprotection was noted to be higher against influenza A strains (H1N1 and H3N2) than against B strains (P < 0.001).

When comparing seroprotection between different age groups (age <65 versus ≥65), the younger group demonstrated higher rates of seroprotection at an HI titer of ≥1:160 compared to the older group against H1N1 (odds ratio, 2.39 [95% CI, 1.44–3.96]; P < 0.001) and B strains. There was no significant difference in seroprotection rate against H3N2 across age groups. Assessing whether there was an interaction between age group and vaccine type was limited by the small number of patients receiving SD-IIV4 who were younger than 65 years. Further analyses could also account for presence of immune-modulating medications, which have been associated with lower likelihood of seroresponse to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA vaccines in maintenance dialysis patients.

This study by Manley et al adds a further dimension to this literature by demonstrating the strength and durability of seroprotection elicited by HD-IIV3 compared with SD-IIV4 and RIV4 in the maintenance dialysis population. Patients with kidney failure have impaired immune function related to uremia-associated changes in the innate and adaptive immune system, oxidative stress, intestinal dysbiosis, and premature immunological aging. During the influenza A(H1N1) pandemic in 2009, a study found that patients receiving hemodialysis had a diminished seroresponse to an adjuvanted H1N1 vaccine compared with healthy individuals. Namely, approximately 64% of hemodialysis patients showed a positive response, versus 98% of healthy patients. Nonetheless, the seroresponse improved upon administration of a second dose. This prior work highlights the need for dedicated studies in the hemodialysis population of influenza vaccine immunogenicity and efficacy.

In addition to these promising clinical data in support of HD-IIV3, Manley et al illustrate how dialysis facility protocols can be used as a source of exogenous variation, creating a quasi-experiment that may reduce unmeasured confounding. Ultimately, the infrastructure of large dialysis organizations could be used to conduct a pragmatic cluster-randomized clinical trial comparing high-dose, standard-dose, and recombinant influenza vaccines and their impact on influenza-like illnesses, hospitalizations, and influenza-associated deaths. Given the waning seroprotection seen with SD-IIV4 and RIV4, the timing of vaccine administration could also be evaluated. Embedded pragmatic trials in a dialysis population have been shown to be feasible, although adequate power and data capture of clinical outcomes remain a challenge. Generating additional high-quality evidence of the efficacy and cost-effectiveness of influenza vaccine formulations is a worthwhile goal to decrease influenza-associated morbidity among maintenance hemodialysis patients.

Article Information

Authors’ Full Names and Academic Degrees: Tarek Barbar, MD, Sri Lekha Tummalapalli, MD, MBA, MAS, and Jeffrey Silberzweig, MD.

Authors’ Affiliations: Division of Nephrology & Hypertension, Department of Medicine, Weill Cornell Medicine, New York, New York (TB, SLT, JS); The Rogosin Institute, New York, New York (SLT, JS); and Division of Healthcare Delivery Science & Innovation, Department of Population Health Sciences, Weill Cornell Medicine, New York, New York (SLT).

Address for Correspondence: Jeffrey Silberzweig, MD, The Rogosin Institute, 505 East 70th St, New York, NY 10021. Email: js2003@nyu.org

Support: No funding supported this work.

Financial Disclosure: Dr Tummalapalli reports consulting for Bayer AG and research funding from Scanwell Health, unrelated to this editorial. Dr Silberzweig reports consulting fees from Alkahest, Bayer AG, and Kaneka unrelated to this work and co-chairs the American Society of Nephrology COVID-19 Response Team and Emergency Partnership Initiative. Dr Barbar declares that he has no relevant financial interests.

Peer Review: Received February 16, 2022, in response to an invitation from the journal. Accepted February 20, 2022, after editorial review by an Associate Editor and a Deputy Editor.

Publication Information: © 2022 by the National Kidney Foundation, Inc. Published online May 27, 2022 with doi 10.1053/j.ajkd.2022.02.014

References

1. Gilbertson DT, Rothman KJ, Chertow GM, et al. Excess deaths attributable to influenza-like illness in the ESRD population. J Am Soc Nephrol. 2019;30(2):346-353.
2. Sellers SA, Hagan RS, Hayden FG, Fischer WA. The hidden burden of influenza: a review of the extra-pulmonary complications of influenza infection. Influenza Other Respir Viruses. 2017;11(5):372-393.
3. DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014;371(7):635-645.
4. DiazGranados CA, Robertson CA, Talbot HK, Landolfi V, Dunning AJ, Greenberg DP. Prevention of serious events in adults 65 years of age or older: a comparison between high-dose and standard-dose inactivated influenza vaccines [in English]. Vaccine. 2015;33(38):4988-4993.
5. Freedman MS, Bernstein H, Ault KA. Advisory Committee on Immunization Practices. Recommended adult immunization schedule, United States, 2021. Ann Intern Med. 2021;174(3):374-384.
6. Krueger KM, Ison MG, Ghoseein C. Practical guide to vaccination in all stages of CKD, including patients treated...
by dialysis or kidney transplantation. *Am J Kidney Dis.* 2020;75(3):417-425.

7. Centers for Medicare & Medicaid Services. Seasonal Influenza Vaccines Pricing. Accessed February 5, 2022. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/VaccinesPricing

8. Remschmidt C, Wichmann O, Harder T. Influenza vaccination in patients with end-stage renal disease: systematic review and assessment of quality of evidence related to vaccine efficacy, effectiveness, and safety. *BMC Med.* 2014;12(1):1-14.

9. Miskulin DC, Weiner DE, Tighiouart H, et al. High-dose seasonal influenza vaccine in patients undergoing dialysis. *Clin J Am Soc Nephrol.* 2018;13(11):1703-1711.

10. Butler AM, Layton JB, Dharnidharka VR, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccine among patients receiving maintenance hemodialysis. *Am J Kidney Dis.* 2020;75(1):72-83.

11. Manley HJ, Lacson EK, Aweh G, et al. Seroresponse to inactivated and recombinant influenza vaccines among maintenance hemodialysis patients. *Am J Kidney Dis.* 2022;80(3):309-318.

12. Hsu CM, Weiner DE, Aweh GN, et al. Seroresponse to SARS-CoV-2 vaccines among maintenance dialysis patients. *Am J Kidney Dis.* 2022;79(2):307-310.

13. Syed-Ahmed M, Narayanan M. Immune dysfunction and risk of infection in chronic kidney disease. *Adv Chronic Kidney Dis.* 2019;26(1):8-15.

14. Dikow R, Eckerle I, Ksoll-Rudek D, et al. Immunogenicity and efficacy in hemodialysis patients of an AS03A-adjuvanted vaccine for 2009 pandemic influenza A(H1N1): a non-randomized trial. *Am J Kidney Dis.* 2011;57(5):716-723.

15. Dember LM, Lacson E, Brunelli SM, et al. The TiME trial: a fully embedded, cluster-randomized, pragmatic trial of hemodialysis session duration. *J Am Soc Nephrol.* 2019;30(5):890-903.